Larimar Shares Jump Premarket on Breakthrough Therapy Designation for Lead Compound

Dow Jones02-24

By Robb M. Stewart

Larimar Therapeutics' shares rallied ahead of the opening bell after the biotechnology company's lead compound received breakthrough therapy designation from the Food and Drug Administration.

In premarket trading, the shares were 29% higher at $3.63. The stock had been down so far in February, and had lost 23% over the last three months.

Larimar on Tuesday said nomlabofusp, a protein replacement therapy that is being developed as a potential treatment for Friedreich's ataxia, was granted the important designation that is designed to expedite the development and regulatory review of drugs targeting serious conditions.

The company said breakthrough therapy designation and FDA feedback on its submission were based on the regulator's review of available clinical data from an ongoing open label study evaluating nomlabofusp in adult and pediatric patients with Friedreich's ataxia.

Larimar is targeting a biologics license application submission in June, backed by topline open-label study data that is expected in the second quarter.

Write to Robb M. Stewart at robb.stewart@wsj.com

(END) Dow Jones Newswires

February 24, 2026 07:37 ET (12:37 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2613719522?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 20:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613719522","market":"nz","top_or_hot":-1,"title":"Larimar Shares Jump Premarket on Breakthrough Therapy Designation for Lead Compound","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Robb M. Stewart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Larimar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' shares rallied ahead of the opening bell after the biotechnology company's lead compound received breakthrough therapy designation from the Food and Drug Administration. \n</p>\n<p>\n  In premarket trading, the shares were 29% higher at $3.63. The stock had been down so far in February, and had lost 23% over the last three months. \n</p>\n<p>\n  Larimar on Tuesday said nomlabofusp, a protein replacement therapy that is being developed as a potential treatment for Friedreich's ataxia, was granted the important designation that is designed to expedite the development and regulatory review of drugs targeting serious conditions. \n</p>\n<p>\n  The company said breakthrough therapy designation and FDA feedback on its submission were based on the regulator's review of available clinical data from an ongoing open label study evaluating nomlabofusp in adult and pediatric patients with Friedreich's ataxia. \n</p>\n<p>\n  Larimar is targeting a biologics license application submission in June, backed by topline open-label study data that is expected in the second quarter. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Robb M. Stewart at robb.stewart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 24, 2026 07:37 ET (12:37 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Larimar Shares Jump Premarket on Breakthrough Therapy Designation for Lead Compound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLarimar Shares Jump Premarket on Breakthrough Therapy Designation for Lead Compound\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-24 20:37</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Robb M. Stewart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Larimar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' shares rallied ahead of the opening bell after the biotechnology company's lead compound received breakthrough therapy designation from the Food and Drug Administration. \n</p>\n<p>\n  In premarket trading, the shares were 29% higher at $3.63. The stock had been down so far in February, and had lost 23% over the last three months. \n</p>\n<p>\n  Larimar on Tuesday said nomlabofusp, a protein replacement therapy that is being developed as a potential treatment for Friedreich's ataxia, was granted the important designation that is designed to expedite the development and regulatory review of drugs targeting serious conditions. \n</p>\n<p>\n  The company said breakthrough therapy designation and FDA feedback on its submission were based on the regulator's review of available clinical data from an ongoing open label study evaluating nomlabofusp in adult and pediatric patients with Friedreich's ataxia. \n</p>\n<p>\n  Larimar is targeting a biologics license application submission in June, backed by topline open-label study data that is expected in the second quarter. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Robb M. Stewart at robb.stewart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 24, 2026 07:37 ET (12:37 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LRMR","symbol_name":"Larimar Therapeutics, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2613719522","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613719522","pubTimestamp":1771936620,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Larimar Therapeutics' shares rallied ahead of the opening bell after the biotechnology company's lead compound received breakthrough therapy designation from the Food and Drug Administration.In premarket trading, the shares were 29% higher at $3.63. The stock had been down so far in February, and had lost 23% over the last three months.Larimar on Tuesday said nomlabofusp, a protein replacement therapy that is being developed as a potential treatment for Friedreich's ataxia, was granted the important designation that is designed to expedite the development and regulatory review of drugs targeting serious conditions.The company said breakthrough therapy designation and FDA feedback on its submission were based on the regulator's review of available clinical data from an ongoing open label study evaluating nomlabofusp in adult and pediatric patients with Friedreich's ataxia.Larimar is targeting a biologics license application submission in June, backed by topline open-label study data tha","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LRMR":"Larimar Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"由于先导化合物被指定为突破性疗法，Larimar股价盘前上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LRMR":0.9},"content_text":"By Robb M. Stewart \n\n\n \n\n\n  Larimar Therapeutics' shares rallied ahead of the opening bell after the biotechnology company's lead compound received breakthrough therapy designation from the Food and Drug Administration. \n\n\n  In premarket trading, the shares were 29% higher at $3.63. The stock had been down so far in February, and had lost 23% over the last three months. \n\n\n  Larimar on Tuesday said nomlabofusp, a protein replacement therapy that is being developed as a potential treatment for Friedreich's ataxia, was granted the important designation that is designed to expedite the development and regulatory review of drugs targeting serious conditions. \n\n\n  The company said breakthrough therapy designation and FDA feedback on its submission were based on the regulator's review of available clinical data from an ongoing open label study evaluating nomlabofusp in adult and pediatric patients with Friedreich's ataxia. \n\n\n  Larimar is targeting a biologics license application submission in June, backed by topline open-label study data that is expected in the second quarter. \n\n\n \n\n\n  Write to Robb M. Stewart at robb.stewart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 24, 2026 07:37 ET (12:37 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2613719522","isCrawlerRequest":true}